A multicenter randomized phase II trial assessing the efficacy and safety of mCapOX plus cetuximab with mFOLFOX6 plus cetuximab as first-line treatment for RAS/BRAF wild-type metastatic colorectal cancer: Updated results from the CAPCET study.
Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Qiu Meng, Yuwen Zhou, Ping Chen, Jin Wang, Yongdong Jin, Yan Li, Chuan Chen, Hong Qiu, Yanmin Shen, Qing Qiao, Hao Liu, Li Huang, Lin Xie, Yanhong Deng, Lei Yang, Li Zhang, Xiaofen Li, Jianjun Li, Shisheng Tan, Tao Zhang
Institutions: Sichuan University, West China Hospital of Sichuan University, Ningxia Medical University, Ningxia Medical University General Hospital, Mianyang Central Hospital, Sichuan Cancer Hospital, Army Medical University, Daping Hospital, Tongji Hospital, Huazhong University of Science and Technology, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, Gannan Medical University, First Affiliated Hospital of Gannan Medical University, Sun Yat-sen University, Sixth Affiliated Hospital of Sun Yat-sen University, Panzhihua University, Chongqing University, West China Medical Center of Sichuan University, Southwest Hospital, Guizhou Provincial People's Hospital, The Affiliated Yongchuan Hospital of Chongqing Medical University
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7162570910
Cites:
Cited by:
Related to: